SG10201803618RA - Compounds for positron emission tomography - Google Patents
Compounds for positron emission tomographyInfo
- Publication number
- SG10201803618RA SG10201803618RA SG10201803618RA SG10201803618RA SG10201803618RA SG 10201803618R A SG10201803618R A SG 10201803618RA SG 10201803618R A SG10201803618R A SG 10201803618RA SG 10201803618R A SG10201803618R A SG 10201803618RA SG 10201803618R A SG10201803618R A SG 10201803618RA
- Authority
- SG
- Singapore
- Prior art keywords
- compounds
- positron emission
- emission tomography
- radical
- radionuclide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nuclear Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361904387P | 2013-11-14 | 2013-11-14 | |
| US201361904400P | 2013-11-14 | 2013-11-14 | |
| US201361909822P | 2013-11-27 | 2013-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201803618RA true SG10201803618RA (en) | 2018-06-28 |
Family
ID=53058011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201803618RA SG10201803618RA (en) | 2013-11-14 | 2014-11-13 | Compounds for positron emission tomography |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20160287731A1 (ko) |
| EP (3) | EP3069147A4 (ko) |
| JP (5) | JP6464166B2 (ko) |
| KR (1) | KR102457827B1 (ko) |
| CN (2) | CN108514646B (ko) |
| AU (3) | AU2014348601A1 (ko) |
| BR (1) | BR112016010927A2 (ko) |
| CA (1) | CA2930581A1 (ko) |
| EA (1) | EA035171B1 (ko) |
| IL (2) | IL245612A0 (ko) |
| MX (2) | MX2016006219A (ko) |
| SG (1) | SG10201803618RA (ko) |
| TW (1) | TWI657827B (ko) |
| WO (1) | WO2015073678A1 (ko) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2187965T3 (pl) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| SG10201706618UA (en) | 2012-11-15 | 2017-09-28 | Endocyte Inc | Conjugates for treating diseases caused by psma expressing cells |
| EP3495355A1 (en) | 2013-10-18 | 2019-06-12 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| WO2017054907A1 (en) | 2015-09-30 | 2017-04-06 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer |
| US10688200B2 (en) * | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| WO2017117687A1 (en) | 2016-01-10 | 2017-07-13 | British Columbia Cancer Agency Branch | 18/19f-labelled compounds which target the prostate specific membrane antigen |
| EP3493851A4 (en) * | 2016-08-02 | 2020-06-24 | ISI Life Sciences, Inc. | NEW SCAFFOLDS FOR THE INTRACELLULAR ADMINISTRATION OF COMPOUNDS FOR THE DETECTION OF CANCER CELLS. |
| US10239891B2 (en) | 2017-05-15 | 2019-03-26 | Indicator Systems International, Inc. | Compositions to detect remnant cancer cells |
| EP3493855A4 (en) | 2016-08-02 | 2020-04-01 | ISI Life Sciences, Inc. | METHOD FOR DETECTION OF CANCER CELLS. |
| JP7231536B2 (ja) | 2016-08-10 | 2023-03-01 | キャンサー ターゲテッド テクノロジー エルエルシー | キレート化されたｐｓｍａ阻害剤 |
| WO2018098390A1 (en) * | 2016-11-23 | 2018-05-31 | Cancer Targeted Technology Llc | Albumin-binding psma inhibitors |
| CN106632341A (zh) * | 2016-12-27 | 2017-05-10 | 天津阿尔塔科技有限公司 | 一种d‑叶酸的合成方法 |
| US10753942B2 (en) | 2017-05-15 | 2020-08-25 | Indicator Systems International, Inc. | Methods to detect remnant cancer cells |
| WO2019246445A1 (en) * | 2018-06-20 | 2019-12-26 | The Research Foundation For The State University Of New York | Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same |
| CN108997170B (zh) * | 2018-08-07 | 2021-04-06 | 贾国苓 | 一种易碱解多羧基螯合物及其制备工艺 |
| WO2020108753A1 (en) * | 2018-11-28 | 2020-06-04 | ITM Isotopen Technologien München AG | Novel tumor antigen binding agents and uses thereof |
| CA3144094A1 (en) | 2019-06-21 | 2020-12-24 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| CN110627837A (zh) * | 2019-09-10 | 2019-12-31 | 齐鲁工业大学 | 一种检测一氧化碳的金属有机框架材料及制备方法和应用 |
| WO2022006007A1 (en) * | 2020-06-29 | 2022-01-06 | The General Hospital Corporation | Methods for imaging bacterial infections |
| WO2022204065A1 (en) * | 2021-03-20 | 2022-09-29 | The Research Foundation For The State University Of New York | Iron(iii) macrocyclic complexes with mixed hyroxyl pendants as mri contrast agents |
| EP4323017A1 (en) * | 2021-04-16 | 2024-02-21 | Novartis AG | Folate receptor-targeted radiotherapeutic agents and their use |
| CN114028590B (zh) * | 2021-11-18 | 2022-09-06 | 北京大学 | 颗粒酶b靶向配合物、放射性药物及其制备方法和应用 |
| WO2023164161A2 (en) * | 2022-02-24 | 2023-08-31 | Purdue Research Foundation | Conjugates, compositions, and methods for hydroxyapatite-targeted imaging and therapy |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795877A (en) | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5863536A (en) | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
| US5672592A (en) | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
| US5902817A (en) | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
| US5962521A (en) | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
| US6093382A (en) * | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| AUPQ014799A0 (en) * | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
| US6692724B1 (en) * | 1999-10-25 | 2004-02-17 | Board Of Regents, The University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
| JP5448284B2 (ja) * | 2000-06-02 | 2014-03-19 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | エチレンジシステイン（ｅｃ）−薬物結合体 |
| ATE427948T1 (de) | 2001-04-24 | 2009-04-15 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
| DK2260875T3 (da) * | 2002-05-06 | 2014-06-30 | Endocyte Inc | Folatreceptor-targetede billeddannelsesmidler |
| US7597876B2 (en) * | 2007-01-11 | 2009-10-06 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
| DK1592457T3 (da) | 2003-01-27 | 2012-10-22 | Endocyte Inc | Folat-vinblastin-konjugat som lægemiddel |
| CN100381177C (zh) * | 2003-01-27 | 2008-04-16 | 恩多塞特公司 | 维生素受体结合递药缀合物 |
| US20050085417A1 (en) * | 2003-10-16 | 2005-04-21 | Thomas Jefferson University | Compounds and methods for diagnostic imaging and therapy |
| WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
| JP5175723B2 (ja) * | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
| CN103893778A (zh) | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | 多药物配体缀合物 |
| EP1940841B9 (fr) * | 2005-10-07 | 2017-04-19 | Guerbet | Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium |
| US9265746B2 (en) * | 2006-05-31 | 2016-02-23 | Merck & Cie | Method for cell-specific targeting |
| US10925977B2 (en) * | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
| CN103372221B (zh) * | 2007-01-11 | 2016-08-24 | 免疫医学股份有限公司 | 用于蛋白质、肽和其他分子的改进的f-18标记的方法和组合物 |
| EP2109466B1 (en) * | 2007-02-07 | 2014-11-12 | Purdue Research Foundation | Positron emission tomography imaging method |
| WO2008101231A2 (en) * | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| AU2008268432B2 (en) | 2007-06-25 | 2015-01-15 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
| CN104774175B (zh) * | 2007-06-26 | 2019-04-16 | 约翰·霍普金斯大学 | 标记的前列腺特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途 |
| PL2187965T3 (pl) * | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
| ES2376175T3 (es) * | 2007-09-28 | 2012-03-09 | Bind Biosciences, Inc. | Direccionamiento a células de c�?ncer usando nanopart�?culas. |
| US8685937B2 (en) * | 2008-08-09 | 2014-04-01 | University Of Iowa Research Foundation | Nucleic acid aptamers |
| CA3035532C (en) * | 2009-03-19 | 2021-10-26 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
| US20120322741A1 (en) * | 2010-02-25 | 2012-12-20 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| US9951324B2 (en) * | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| CN101863924B (zh) * | 2010-05-17 | 2012-06-27 | 北京师范大学 | 99mTc标记肼基烟酰胺基-二氧辛酰-叶酸配合物及制备方法 |
| EP2739316B1 (en) * | 2011-08-05 | 2019-04-10 | Molecular Insight Pharmaceuticals, Inc. | Radiolabeled prostate specific membrane antigen inhibitors |
| WO2013130776A1 (en) * | 2012-02-29 | 2013-09-06 | Purdue Research Foundation | Folate receptor alpha binding ligands |
| CA2887727A1 (en) * | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
| US20160199500A1 (en) * | 2013-08-22 | 2016-07-14 | Syracuse University | Compositions comprising vitamin b12 and intrinsic factor and methods of use thereof |
| CN103951668A (zh) * | 2014-04-25 | 2014-07-30 | 广州军区广州总医院 | 叶酸衍生物的正电子核素标记物及其应用 |
-
2014
- 2014-11-13 CN CN201810300332.XA patent/CN108514646B/zh active Active
- 2014-11-13 EP EP14861854.9A patent/EP3069147A4/en not_active Withdrawn
- 2014-11-13 JP JP2016529948A patent/JP6464166B2/ja active Active
- 2014-11-13 US US15/035,936 patent/US20160287731A1/en not_active Abandoned
- 2014-11-13 WO PCT/US2014/065467 patent/WO2015073678A1/en active Application Filing
- 2014-11-13 EP EP19167560.2A patent/EP3533473A3/en not_active Withdrawn
- 2014-11-13 AU AU2014348601A patent/AU2014348601A1/en not_active Abandoned
- 2014-11-13 CN CN201480071256.XA patent/CN105849568B/zh active Active
- 2014-11-13 SG SG10201803618RA patent/SG10201803618RA/en unknown
- 2014-11-13 EP EP20180928.2A patent/EP3777898A3/en active Pending
- 2014-11-13 BR BR112016010927A patent/BR112016010927A2/pt active Search and Examination
- 2014-11-13 CA CA2930581A patent/CA2930581A1/en active Pending
- 2014-11-13 KR KR1020167015740A patent/KR102457827B1/ko active IP Right Grant
- 2014-11-13 MX MX2016006219A patent/MX2016006219A/es unknown
- 2014-11-13 EA EA201690862A patent/EA035171B1/ru unknown
- 2014-11-14 TW TW103139664A patent/TWI657827B/zh active
-
2016
- 2016-05-11 IL IL245612A patent/IL245612A0/en active IP Right Grant
- 2016-05-12 MX MX2022014611A patent/MX2022014611A/es unknown
-
2018
- 2018-08-20 IL IL261259A patent/IL261259B/en active IP Right Grant
- 2018-10-10 US US16/157,024 patent/US20190275181A1/en not_active Abandoned
- 2018-11-06 JP JP2018208786A patent/JP2019023232A/ja active Pending
-
2020
- 2020-03-30 JP JP2020060644A patent/JP2020165975A/ja active Pending
-
2021
- 2021-01-07 AU AU2021200067A patent/AU2021200067B2/en active Active
- 2021-09-29 US US17/488,810 patent/US20220125958A1/en active Pending
- 2021-10-27 JP JP2021175168A patent/JP7299285B2/ja active Active
-
2023
- 2023-05-02 AU AU2023202704A patent/AU2023202704A1/en active Pending
- 2023-06-15 JP JP2023098521A patent/JP2023107988A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014611A (es) | Compuestos para tomografia por emision de positrones. | |
| MX2021008977A (es) | Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata. | |
| MX2018008168A (es) | Inhibidores de antigenos de membrana especificos de la prostata (psma) basados en la urea para imaginologia y terapia. | |
| MX2022002401A (es) | Productos radiofarmaceuticos, agentes de radioimagenologia,y uso de los mismos. | |
| MX2015008993A (es) | Radiofarmaceuticos y agentes de radio-formacion de imagen a base de triazina. | |
| PH12015501996A1 (en) | Heterocyclic compounds and uses thereof | |
| MX2017003886A (es) | Conjugado radiofarmaceutico de un metabolito y un agente epr para tratar celulas tumorales. | |
| WO2014152389A8 (en) | Imaging agent for detection of diseased cells | |
| MX343405B (es) | Complejos que emiten alfa-particulas objetivo que comprenden radionuclido de torio e hidroxipiridinona que contiene ligando. | |
| NZ739770A (en) | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer | |
| MX2018000239A (es) | Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. | |
| MX2013012793A (es) | Aminoacidos radiomarcados para imagen de diagnostico. | |
| PH12020551471A1 (en) | Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer | |
| MX2019001053A (es) | Inhibidores de antigeno de la membrana especifico para la prostata (psma) quelados. | |
| JP2014508784A5 (ko) | ||
| MX2016003725A (es) | Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau. | |
| NZ758917A (en) | Compounds for positron emission tomography | |
| WO2013113801A3 (en) | Chelating agents | |
| EA202090575A3 (ru) | Соединения для позитронно-эмиссионной томографии | |
| NZ708849A (en) | Radiopharmaceutical products for diagnosis and therapy of adrenal carcinoma | |
| MX336322B (es) | 99mtc-edda/hynic-ggc-aunp-manosa como un nuevo radiofarmaco para la deteccion del ganglio centinela en cancer de mama. |